# Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Source: https://onco.cc/trials/nct07087054/  
OnCo record `nct07087054` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Paltusotine in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by Crinetics Pharmaceuticals Inc., now recruiting.

## Summary

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen is a phase 3 interventional study registered as NCT07087054 by Crinetics Pharmaceuticals Inc., with 141 participants planned, started 2025-11-19 and due to reach its primary completion in 2027-08. Interventions recorded: Paltusotine and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07087054
- Phase: 3
- Setting: A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors
- Sponsor: Crinetics Pharmaceuticals Inc.
- Enrolled: 141

## Sources

- ClinicalTrials.gov NCT07087054: https://clinicaltrials.gov/study/NCT07087054

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Crinetics Pharmaceuticals](https://onco.cc/companies/crinetics-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct07087054.json